ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1507	National Cancer Institute	Html	en	Extragonadal Germ Cell Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of extragonadal germ cell tumors.	residual mass 0.384023 large tumor volume 0.30085 residual disease. 0.273583 recurrent testicular cancer. 0.3175 cisplatin-based chemotherapy regimens 0.371374 PDQ cancer information 0.391809 bulky tumors 0.328858 nonseminoma germ cell 0.421124 cell tumors. 0.272309 nonseminomatous germ cell 0.40313 clinical trials 0.311324 relatively small tumors 0.373793 germ cells 0.335003 particularly young individuals 0.307507 Initial chemotherapy 0.290755 cancer information summary 0.37005 breast cancer prevention 0.298248 careful testicular examination 0.334354 Initial debulking surgery 0.299396 extragonadal primary tumors 0.367991 patients 0.377174 BEP regimen 0.273424 NCI’s PDQ 0.288373 PDQ Adult Treatment 0.321273	NCI PDQ cancer 0.337916 Craniospinal radiation therapy 0.306681 extragonadal germ cell 0.679693 international germ cell 0.403901 tumor prognostic classification 0.317369 overall survival rates 0.302813 long-term disease-free survival 0.296962 chemotherapy course 0.295979 major clinical trial 0.309884 autologous bone marrow 0.294582 advanced disseminated germ 0.372421 seminomatous germ cell 0.403127 nonseminomatous extragonadal germ 0.370944 testicular seminoma 0.333059 serum alpha fetoprotein 0.309001 high-risk patients 0.281542 larger residual masses 0.321492 National Cancer Institute 0.298826 PDQ documents 0.279503 nonseminoma testicular cancer 0.332786 nonlocalized tumors 0.326576 germ cell tumors 0.92252 residual mass posttreatment 0.32699 Hematologic toxic effects 0.298226	CLICK HERE
1804	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama).	Surgical Adjuvant Breast 0.311283 node-positive breast 0.305691 susceptibility to breast 0.306299 results from 0.304936 node-negative breast carcinoma 0.307067 linfáticos internos mamarios 0.304657 invasive breast 0.310223 MammaPrint breast 0.305772 metástasis manifiesta 0.303936 Breast Cancer Family 0.311467 invasive breast carcinoma 0.30652 breast magnetic resonance 0.305716 Breast Cancer Linkage 0.318171 with node-negative breast 0.307174 brca2 mutation 0.31001 early breast 0.305558 Metástasis ipsilateral rodaderab 0.30419 Cancer Linkage Consortium 0.309543 risk factors 0.310931 ganglio centinela 0.304343 mucinous breast carcinomas 0.305818 Natl Cancer Inst 0.352497 breast carcinomas 0.328163 Women's Health Initiative 0.304548 node-negative breast 0.315228	N2b Metástasis 0.303847 from benign breast 0.306434 N2a Metástasis 0.30385 BRCA2 mutation carriers 0.309625 investigation into cancer 0.309168 Bilateral breast carcinoma 0.306729 ganglios positivos.Se 0.305633 Lancet Oncol 0.305043 contralateral breast 0.320411 lobular breast 0.305977 benign breast 0.312903 ganglio linfático centinela 0.333143 ganglios satélites 0.30541 Cancer Staging Manual 0.308858 Cancer Res Treat 0.315484 Clin Oncol 0.389208 breast carcinomas distinguish 0.305804 breast cancer 0.999811 Relat Cancer 0.305724 BRCA2-associated breast 0.305731 with invasive breast 0.307222 family history 0.30714 AJCC Cancer Staging 0.309184 Breast Cancer Res 0.348498	CLICK HERE
1832	National Cancer Institute	Html	es	Tratamiento del cáncer de vagina (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vagina.	Obstet Gynecol 0.283662 Lippincott Williams 0.242575 vagina funcional 0.243946 berek js 0.239666 Carlone M 0.228988 prognostic factors 0.719083 vaginal cancer 0.473271 Sin embargo 0.237061 American Cancer Society 0.229383 Frank SJ 0.247276 Definitive radiotherapy 0.277726 institutional experience 0.233025 Radiat Oncol Biol 0.893767 DeVita VT Jr 0.277942 Camel HM 0.230789 Jhingran A 0.245715 Gynecol Oncol 0.996446 Rosenberg SA 0.240229 primary invasive squamous 0.2365 squamous carcinoma 0.334954 Lee P 0.243278 Galakatos AE 0.229807 vagina treated with 0.406995 primary carcinoma 0.405837 Markman MA 0.223742	estadio ii 0.224737 Seski J 0.269409 vaginal intraepithelial neoplasia 0.27229 Perez CA 0.260508 Wheeler JA 0.267137 Cancer Staging Manual 0.259578 Levenback C 0.24589 Definitive irradiation 0.237883 Chen AS 0.271634 Eifel PJ 0.224915 PDQ Tratamiento 0.250686 New York 0.251038 long-term evaluation 0.231124 9th ed 0.223747 Zagars GK 0.268986 Oncol Biol Phys 0.938039 invasive squamous carcinoma 0.314957 Dundas G 0.228633 Treat Options Oncol 0.229038 cuello uterino 0.451234 Gynecol Cancer 0.242612 Twenty-year review 0.228463 AJCC Cancer Staging 0.261483 squamous cell carcinoma 0.643647	CLICK HERE
1890	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama).	estadio lllC 0.524041 siguientes procedimientos 0.510716 siguientes aspectos 0.534365 causa efectos 0.516747 estadio lllB 0.524512 estadio lllA 0.524967 rayos x 0.508877 causó hinchazón 0.508591 cuáles lesiones 0.508991 Breast Cancer Risk 0.519727 epidérmico humano tipo 0.51911 carcinoma lobulillar 0.618686 crecimiento llamada her2 0.513006 cuerpo llamada ecograma 0.530459 pared torácica.ampliar mastectomía 0.517551 siguientes estadios 0.514163 proteína tipo factor 0.510936 células madre 0.671831 estadio iv 0.594708 ganglio linfático centinela 0.990128 Oncotype DX 0.510563 estadio ib 0.547143 prueba ayuda 0.524997 enlace drugs approved 0.56421 estadio ia 0.546556	mama.ampliar cirugía 0.509968 CLIS.Ampliar Carcinoma lobulillar 0.520349 efectos tardíos 0.515275 proteína her2 0.510017 Características genéticas 0.510197 bulbos minúsculos 0.511767 Breast Cancer Treatment 0.519669 cuántos genes 0.511329 incisión separada.ampliar mastectomía 0.517497 estadio iiia 0.543785 antecedentes familiares 0.532316 cabo pruebas 0.51404 estadio iiic 0.596075 estadio llB 0.525023 estadio llA 0.525437 Gynecologic Cancers 0.511174 mama.ampliar mamografía 0.511179 proteína llamada mTOR 0.510238 Breast Cancer 0.623769 sección cáncer 0.744984 pequeñas llamadas lobulillos 0.518854 genes brca1 0.512161 siguientes pruebas 0.535819 siguientes sumarios 0.517679	CLICK HERE
1934	National Cancer Institute	Html	es	Tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo.	siguientes procedimientos 0.506474 células madre 0.526262 pequeña cantidad 0.50899 siguientes especialistas 0.504251 siguientes tipos 0.504112 rayos x 0.523233 tejido óseo 0.519779 enlace drugs approved 0.505077 suficiente tejido 0.503088 fibroso maligno óseo 0.821835 efectos tardíos 0.529504 PDQ Efectos tardíos 0.509684 National Cancer Institute 0.502454 siguientes riesgos 0.501964 médula ósea también 0.505126	Instituto Nacional 0.509248 PDQ Tratamiento 0.523403 determinados cambios 0.501954 alta potencia 0.503883 nuevos tipos 0.503233 Physician Data Query 0.509387 cáncer óseo 0.512408 siguientes situaciones 0.505889 Bone Cancer 0.502772 siguientes enlaces 0.502451 células sanguíneas maduras 0.509706 célula madre 0.502683 siguientes pruebas 0.512226 fibroso maligno 0.960799	CLICK HERE
3653	National Cancer Institute	Html	es	Cannabis y canabinoides (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso del Cannabis y canabinoides para el tratamiento de los efectos secundarios relacionados con el tratamiento del cáncer como la náusea y el vómito.	suficiente información 0.303746 American Academy 0.304933 salud masculina 0.30438 Controlled Substances Act 0.309374 estado.ampliar mapa 0.305022 NCI Best Case 0.309795 Ley Boggs 0.304951 ratones modelo 0.329727 Asia central 0.304897 datos bibliográficos pubmed 0.306457 principal canabinoide 0.317402 continuas preocupaciones 0.305444 Instituto Nacional 0.356831 distintos métodos 0.304585 Salud Complementaria 0.311676 Asociación Médica Americana 0.308343 complementarias revisa 0.305401 huésped aguda 0.30517 posibles efectos 0.307656 siglo xix 0.305316 Estados Unidos 0.923075 Investigational New Drug 0.308776 ¿Los beneficios 0.303644 Centro Nacional 0.308445 células madre 0.307765	New Hampshire Avenue 0.305866 creciente interés 0.305364 Drug Administration 0.303686 vía oral 0.438627 medicamentos canabinoides 0.315665 lista i 0.304143 Marijuana Tax Act 0.30965 Men's Health Study 0.308077 siguientes riesgos 0.303989 suficientes pruebas 0.305693 Visuals Online 0.304212 sistema nervioso central 0.330645 Physician Data Query 0.323581 libre uso 0.304331 principal ingrediente 0.304814 receptores canabinoides 0.313898 posibles beneficios 0.304408 página manejo 0.303972 ¿El tratamiento 0.309063 planta cannabis 0.341326 potencial alto 0.304956 medicina complementaria 0.465284 largo tiempo 0.303689 ¿el cannabis 0.355862	CLICK HERE
15908	National Cancer Institute	Html	es	Laetrilo (amigdalina) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del laetrilo (amigdalina) como tratamiento para personas con cáncer.	Natl Acad Sci 0.351583 institute's retrospective laetrile 0.328712 treated with laetrile 0.349302 Exp Med Surg 0.328157 Promoting poison 0.33939 antitumor activity 0.465434 cases treated with 0.28668 treatment with laetrile 0.295229 with laetrile 0.90547 CA Cancer 0.770829 Acta Unio Int 0.423146 Cancer Industry 0.474642 Med Hypotheses 0.298922 Cancer Commission 0.379224 Estados Unidos 0.752083 Amygdalin induces apoptosis 0.284053 Navarro MD 0.430756 Unio Int Contr 0.427919 Five years 0.324596 Ellison NM 0.316229 Bickis IJ 0.282987 Acad Med 0.304051 Ames MM 0.502122 Laetrile toxicity studies 0.333014 Med Assoc 0.356472	Diss Abstr Int 0.346583 years experience with 0.456942 Proc Natl Acad 0.355643 vía oral 0.317497 Laetrile toxicity 0.342269 retrospective laetrile analysis 0.331541 Cancer Establishment 0.478533 experience with laetrile 0.549066 Dorr RT 0.337868 Cancer Institute retrospective 0.411789 Unproven methods 0.542254 Treat Rep 0.798281 current status 0.343299 Intern Med 0.566133 Kovach JS 0.535271 with laetrile therapy 0.559394 Clin Nutr 0.378962 Int Contr Cancrum 0.427916 laetrile intoxication 0.281414 Moertel CG 0.440121 Herbert V 0.324024 NCI Laetrile Review 0.334924 Paxinos J 0.340814 Med Chem 0.296011	CLICK HERE
16684	National Cancer Institute	Html	en	Immunotherapy	Immunotherapy is treatment that helps your immune system fight cancer. Get information about the different types of immunotherapy and what you can expect during treatment.	different ways 0.281527 fatal allergic reactions 0.264895 Certain immunotherapies 0.259316 treatment vaccines 0.275288 cancer cells 0.951751 new healthy cells 0.412417 type 0.312586 adult cancer treatment 0.355067 immune system fight 0.336993 cancer treatment summaries 0.489214 body’s cells 0.328519 white blood cells 0.50706 immune response 0.442108	bladder cancer 0.215882 immunotherapy 0.916869 car t-cell therapy 0.510597 white blood cell 0.291068 biological therapy 0.305661 immune cells 0.541167 normal immune responses 0.430369 immunotherapies 0.36897 different types 0.290719 early skin cancer 0.309312 body fight infections 0.317237 childhood cancer treatment 0.34975 adoptive cell transfer 0.589329	CLICK HERE
16839	National Cancer Institute	Html	en	Previous NCI Alliance Grantees	The NCI Alliance for Nanotechnology in Cancer has funded a multitude of research and training grants since 2005. Find here a list of all of these high impact projects.	cancer-related nanotechnology research 0.909204 initiative 0.300481 private organizations 0.515908 Focus 0.261214 National Cancer Institute 0.829641	clinical practice 0.510503 clinicians 0.293138 areas 0.260532 NCI Alliance 0.657758 major commitment 0.597371	CLICK HERE
16858	National Cancer Institute	Html	en	Monitoring Research Grant Awards	NCI grants management staff regularly monitor individual grants within each budget period and within the overall project period.	program director 0.901745 overall project period 0.737705 Comptroller General 0.577687 documents 0.447442 Grants management officer 0.721935 grants management specialist 0.810551 federal regulation 0.560169 HHS awarding agency 0.720873 NCI staff work 0.714177 assessment 0.459846 progress reports 0.591992 budget period 0.591377 review 0.454674 weaknesses 0.464168 grants management 0.917818 telephone numbers 0.566417 financial reports 0.599567 required retention period 0.705874 reasonable access 0.563534 grant awards 0.568767 responsible GMS 0.614785 award process 0.554431 approved project 0.590335 recipients 0.469243 recipient cash expenditure 0.886855	NCI grants management 0.812999 problems 0.44631 recipient institution 0.874163 United States 0.564008 records 0.447146 audit reports 0.592365 site visits 0.586368 scientific progress 0.547344 Inspector General 0.563508 mutually agreeable course 0.708418 recipient’s inability 0.723309 internal controls 0.570063 Expenditure patterns 0.599349 financial systems 0.589323 pass-through entity 0.56408 monitors individual grants 0.762977 applicant organization 0.594032 unrestricted access 0.5713 principal investigator 0.553317 financial management 0.584417 specific guidelines 0.567884 management systems 0.560429 economic policy 0.555241 grant expenditures 0.689873	CLICK HERE